Enjoy complimentary customisation on priority with our Enterprise License!
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 08: Parent market
*Exhibit 09: Market characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis: Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
***3. Market Sizing
**3.1 Market definition
*Exhibit 11: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 12: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2020 - 2025 ($ million)
*Exhibit 14: Global market: Year-over-year growth 2020 - 2025 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2020 & 2025
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2020
***5. Market Segmentation by Type
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 22: Type - Market share 2020-2025 (%)
**5.2 Comparison by Type
*Exhibit 23: Comparison by Type
**5.3 Ischemic stroke - Market size and forecast 2020-2025
*Exhibit 24: Ischemic stroke - Market size and forecast 2020-2025 ($ million)
*Exhibit 25: Ischemic stroke - Year-over-year growth 2020-2025 (%)
**5.4 Hemorrhagic stroke - Market size and forecast 2020-2025
*Exhibit 26: Hemorrhagic stroke - Market size and forecast 2020-2025 ($ million)
*Exhibit 27: Hemorrhagic stroke - Year-over-year growth 2020-2025 (%)
**5.5 Market opportunity by Type
*Exhibit 28: Market opportunity by Type
***6. Customer landscape
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
**6.1 Overview
*Exhibit 29: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*The regions covered in the report are:
*Exhibit 30: Market share by geography 2020-2025 (%)
**7.2 Geographic comparison
*Exhibit 31: Geographic comparison
**7.3 North America - Market size and forecast 2020-2025
*Exhibit 32: North America - Market size and forecast 2020-2025 ($ million)
*Exhibit 33: North America - Year-over-year growth 2020-2025 (%)
**7.4 Europe - Market size and forecast 2020-2025
*Exhibit 34: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 35: Europe - Year-over-year growth 2020-2025 (%)
**7.5 Asia - Market size and forecast 2020-2025
*Exhibit 36: Asia - Market size and forecast 2020-2025 ($ million)
*Exhibit 37: Asia - Year-over-year growth 2020-2025 (%)
**7.6 ROW - Market size and forecast 2020-2025
*Exhibit 38: ROW - Market size and forecast 2020-2025 ($ million)
*Exhibit 39: ROW - Year-over-year growth 2020-2025 (%)
**7.7 Key leading countries
*Exhibit 40: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 41: Market opportunity by geography ($ million)
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 High-risk factors for stroke
*8.1.2 Growing geriatric population
*8.1.3 Strong pipeline
**8.2 Market challenges
*8.2.1 High level of genericization in the market
*8.2.2 Availability of substitutes
* 8.2.3 Unmet needs for anticoagulant reversal agents
*Exhibit 42: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Development of novel therapies
*8.3.2 Increasing awareness about stroke
*8.3.3 TBI, a value-addition in AIS research
***9. Vendor Landscape
**9.1 Overview
*Exhibit 43: Vendor landscape
**9.2 Landscape disruption
*Exhibit 44: Landscape disruption
*Exhibit 45: Industry risks
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 46: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 47: Market positioning of vendors
**10.3 Amgen Inc.
*Exhibit 48: Amgen Inc. - Overview
*Exhibit 49: Amgen Inc. - Business segments
*Exhibit 50: Amgen Inc. - Key offerings
*Exhibit 51: Amgen Inc. - Segment focus
**10.4 AstraZeneca Plc
*Exhibit 52: AstraZeneca Plc - Overview
*Exhibit 53: AstraZeneca Plc - Product and service
*Exhibit 54: AstraZeneca Plc - Key offerings
**10.5 Bayer AG
*Exhibit 55: Bayer AG - Overview
*Exhibit 56: Bayer AG - Business segments
*Exhibit 57: Bayer AG - Key offerings
*Exhibit 58: Bayer AG - Segment focus
**10.6 Boehringer Ingelheim International GmbH
*Exhibit 59: Boehringer Ingelheim International GmbH - Overview
*Exhibit 60: Boehringer Ingelheim International GmbH - Business segments
*Exhibit 61: Boehringer Ingelheim International GmbH - Key news
*Exhibit 62: Boehringer Ingelheim International GmbH - Key offerings
*Exhibit 63: Boehringer Ingelheim International GmbH - Segment focus
**10.7 Bristol Myers Squibb Co.
*Exhibit 64: Bristol Myers Squibb Co. - Overview
*Exhibit 65: Bristol Myers Squibb Co. - Product and service
*Exhibit 66: Bristol Myers Squibb Co. - Key offerings
**10.8 F. Hoffmann La Roche Ltd.
**Exhibit 67: F. Hoffmann La Roche Ltd. - Overview
**Exhibit 68: F. Hoffmann La Roche Ltd. - Business segments
**Exhibit 69: F. Hoffmann La Roche Ltd. - Key offerings
**Exhibit 70: F. Hoffmann La Roche Ltd. - Segment focus
**10.9 Johnson and Johnson Inc.
*Exhibit 72: Johnson and Johnson Inc. - Business segments
*Exhibit 73: Johnson and Johnson Inc. - Key offerings
**10.10 Merck and Co. Inc.
*Exhibit 75: Merck and Co. Inc. - Overview
*Exhibit 76: Merck and Co. Inc. - Business segments
*Exhibit 77: Merck and Co. Inc. - Key offerings
*Exhibit 78: Merck and Co. Inc. - Segment focus
**10.11 Pfizer Inc.
*Exhibit 79: Pfizer Inc. - Overview
*Exhibit 80: Pfizer Inc. - Business segments
*Exhibit 81: Pfizer Inc. -Key news
*Exhibit 82: Pfizer Inc. - Key offerings
*Exhibit 83: Pfizer Inc. - Segment focus
**10.12 Sanofi SA
*Exhibit 84: Sanofi SA - Overview
*Exhibit 85: Sanofi SA - Business segments
*Exhibit 86: Sanofi SA- Key news
*Exhibit 87: Sanofi SA - Key offerings
*Exhibit 88: Sanofi SA - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 Market definition
*11.1.2 Objectives
*11.1.3 Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 89: Currency conversion rates for US$
**11.3 Research Methodology
*Exhibit 90: Research Methodology
*Exhibit 91: Validation techniques employed for market sizing
*Exhibit 92: Information sources
**11.4 List of abbreviations
*Exhibit 93: List of abbreviations
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.